Sjogren's syndrome: A possible pathogenetic mechanism involving somatostatin

L. Baccaglini, S. R. Pillemer, B. J. Baum

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Sjogren's syndrome is a chronic systemic disease that primarily affects the salivary and lacrimal glands. The pathogenesis of Sjogren's syndrome is unknown. We hypothesize that reduced somatostatin activity is an important factor in promoting immune dysregulation in patients affected by Sjogren's syndrome. Somatostatin is a multifunctional peptide with potent immunomodulatory properties. Its effects include reduced lymphocytic activity, reduced gastric and intestinal secretions, activation of the hypothalamic-pituitary axis, and anti-inflammatory action, all opposite to the general presentation in Sjogren's syndrome. We suggest that the activity of somatostatin is low in patients affected by this disease, and this contributes significantly to the pathology observed.

Original languageEnglish (US)
Pages (from-to)264-266
Number of pages3
JournalOral Diseases
Volume6
Issue number5
StatePublished - Jan 1 2000

Fingerprint

Sjogren's Syndrome
Somatostatin
Intestinal Secretions
Lacrimal Apparatus
Salivary Glands
Stomach
Chronic Disease
Anti-Inflammatory Agents
Pathology
Peptides

Keywords

  • Autoimmunity
  • Hormones
  • Salivary glands
  • Sjogren's syndrome
  • Somatostatin

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Dentistry(all)

Cite this

Sjogren's syndrome : A possible pathogenetic mechanism involving somatostatin. / Baccaglini, L.; Pillemer, S. R.; Baum, B. J.

In: Oral Diseases, Vol. 6, No. 5, 01.01.2000, p. 264-266.

Research output: Contribution to journalArticle

Baccaglini, L. ; Pillemer, S. R. ; Baum, B. J. / Sjogren's syndrome : A possible pathogenetic mechanism involving somatostatin. In: Oral Diseases. 2000 ; Vol. 6, No. 5. pp. 264-266.
@article{fcf9609e18224ce7a0d2334ca997caff,
title = "Sjogren's syndrome: A possible pathogenetic mechanism involving somatostatin",
abstract = "Sjogren's syndrome is a chronic systemic disease that primarily affects the salivary and lacrimal glands. The pathogenesis of Sjogren's syndrome is unknown. We hypothesize that reduced somatostatin activity is an important factor in promoting immune dysregulation in patients affected by Sjogren's syndrome. Somatostatin is a multifunctional peptide with potent immunomodulatory properties. Its effects include reduced lymphocytic activity, reduced gastric and intestinal secretions, activation of the hypothalamic-pituitary axis, and anti-inflammatory action, all opposite to the general presentation in Sjogren's syndrome. We suggest that the activity of somatostatin is low in patients affected by this disease, and this contributes significantly to the pathology observed.",
keywords = "Autoimmunity, Hormones, Salivary glands, Sjogren's syndrome, Somatostatin",
author = "L. Baccaglini and Pillemer, {S. R.} and Baum, {B. J.}",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "264--266",
journal = "Oral Diseases",
issn = "1354-523X",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Sjogren's syndrome

T2 - A possible pathogenetic mechanism involving somatostatin

AU - Baccaglini, L.

AU - Pillemer, S. R.

AU - Baum, B. J.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Sjogren's syndrome is a chronic systemic disease that primarily affects the salivary and lacrimal glands. The pathogenesis of Sjogren's syndrome is unknown. We hypothesize that reduced somatostatin activity is an important factor in promoting immune dysregulation in patients affected by Sjogren's syndrome. Somatostatin is a multifunctional peptide with potent immunomodulatory properties. Its effects include reduced lymphocytic activity, reduced gastric and intestinal secretions, activation of the hypothalamic-pituitary axis, and anti-inflammatory action, all opposite to the general presentation in Sjogren's syndrome. We suggest that the activity of somatostatin is low in patients affected by this disease, and this contributes significantly to the pathology observed.

AB - Sjogren's syndrome is a chronic systemic disease that primarily affects the salivary and lacrimal glands. The pathogenesis of Sjogren's syndrome is unknown. We hypothesize that reduced somatostatin activity is an important factor in promoting immune dysregulation in patients affected by Sjogren's syndrome. Somatostatin is a multifunctional peptide with potent immunomodulatory properties. Its effects include reduced lymphocytic activity, reduced gastric and intestinal secretions, activation of the hypothalamic-pituitary axis, and anti-inflammatory action, all opposite to the general presentation in Sjogren's syndrome. We suggest that the activity of somatostatin is low in patients affected by this disease, and this contributes significantly to the pathology observed.

KW - Autoimmunity

KW - Hormones

KW - Salivary glands

KW - Sjogren's syndrome

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0033808655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033808655&partnerID=8YFLogxK

M3 - Article

C2 - 11002406

AN - SCOPUS:0033808655

VL - 6

SP - 264

EP - 266

JO - Oral Diseases

JF - Oral Diseases

SN - 1354-523X

IS - 5

ER -